Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F6TD
|
|||
| Former ID |
DNC001394
|
|||
| Drug Name |
SUN N4057
|
|||
| Synonyms |
Piclozotan; UNII-FQE44HS7AH; FQE44HS7AH; CHEMBL345237; 182415-09-4; SUN N4057; Piclozotan [INN]; 3-Chloro-4-(4-(4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl)butyl)-1,4-benzoxazepin-5(4H)-one; SCHEMBL562627; URMTUEWUIGOJBW-UHFFFAOYSA-N; SUN N-4057; BDBM50097342; DB12361; L001621; 3-Chloro-4-[4-(3'',6''-dihydro-2''H-[2,4'']bipyridinyl-1''-yl)-butyl]-4H-benzo[f][1,4]oxazepin-5-one; 3-chloro-4,5-dihydro-4-(4-(4-(2-pyridyl)-1,2,5,6-tetrahydropyridin-1-yl)butyl)-1,4-benzoxazepin-5-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coronary artery disease [ICD-11: BA80; ICD-10: I25.1, I25.4] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H24ClN3O2
|
|||
| Canonical SMILES |
C1CN(CC=C1C2=CC=CC=N2)CCCCN3C(=COC4=CC=CC=C4C3=O)Cl
|
|||
| InChI |
1S/C23H24ClN3O2/c24-22-17-29-21-9-2-1-7-19(21)23(28)27(22)14-6-5-13-26-15-10-18(11-16-26)20-8-3-4-12-25-20/h1-4,7-10,12,17H,5-6,11,13-16H2
|
|||
| InChIKey |
URMTUEWUIGOJBW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 182415-09-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Agonist | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00272909) Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI). U.S. National Institutes of Health. | |||
| REF 2 | Experimental study of pharmacological hypothermia: enhanced neuroprotective effect of a novel 5-HT 1 A agonist SUN N4057 by the pharmacological hypothermia. No To Shinkei. 2001 Sep;53(9):853-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.